Affordable Access

Publisher Website

Comparable Long-Term Outcomes of Cyclosporine and Infliximab in Patients With Steroid-Refractory Acute Severe Ulcerative Colitis: A Meta-Analysis

  • Szemes, Kata1
  • Soós, Alexandra2, 3
  • Hegyi, Péter1, 2, 4, 5
  • Farkas, Nelli2, 6
  • Erős, Adrienn2
  • Erőss, Bálint2
  • Mezősi, Emese1
  • Szakács, Zsolt2, 4
  • Márta, Katalin2, 4
  • Sarlós, Patrícia1, 4
  • 1 First Department of Medicine, Medical School, University of Pécs, Pécs , (Hungary)
  • 2 Institute for Translational Medicine, Medical School, University of Pécs, Pécs , (Hungary)
  • 3 Doctoral School of Clinical Medicine, University of Szeged, Szeged , (Hungary)
  • 4 János Szentágothai Research Centre, University of Pécs, Pécs , (Hungary)
  • 5 Momentum Gastroenterology Multidisciplinary Research Group, Hungarian Academy of Sciences, University of Szeged, Szeged , (Hungary)
  • 6 Institute of Bioanalysis, Medical School, University of Pécs, Pécs , (Hungary)
Published Article
Frontiers in Medicine
Frontiers Media SA
Publication Date
Jan 21, 2020
DOI: 10.3389/fmed.2019.00338
PMID: 32039218
PMCID: PMC6985460
PubMed Central


Background: In steroid-refractory acute severe ulcerative colitis (ASUC), cyclosporine (CYS) or infliximab (IFX) may be considered as a second-line alternative to avoid colectomy. There are short-term data reported, but until now, there is no meta-analysis regarding long-term outcomes of CYS and IFX in patients with ASUC. Aim: To compare long-term efficacy and safety of CYS and IFX in a meta-analysis. Methods: Three electronic databases (PubMed, Embase, Cochrane Central Register of Controlled Trials) were searched for studies which compared CYS vs. IFX in adults with ASUC. Long-term colectomy-free rate from 1 to 10 years during CYS or IFX therapy was collected, last updated up to 22nd May 2019. Primary outcome was long-term colectomy-free rate, secondary outcomes were adverse events (AE), serious adverse events (SAE), and mortality. Long-term colectomy-free survival and safety measures were pooled with the random-effect model. Odds ratios (OR) with 95% confidence intervals (CI) were calculated. Results: Data from 1,607 patients in 15 trials were extracted. In the first 3 years, pooled OR for colectomy-free survival was higher with IFX than with CYS (OR = 1.59, 95% CI: 1.11–2.29, p = 0.012; OR = 1.57, 95% CI: 1.14–2.18, p = 0.006; and OR = 1.75, 95% CI: 1.08–2.84, p = 0.024; at 1, 2, and 3 years, respectively). However, the significant difference remained undetected from the fourth year of follow-up and in subgroup of RCTs (OR = 1.35, 95% CI: 0.90–2.01, p = 0.143; OR = 1.41, 95% CI: 0.94–2.12, p = 0.096; and OR = 1.34, 95% CI: 0.89–2.00, p = 0.157; at 1, 2, and 3 years, respectively). No significant difference was detected regarding adverse events, serious adverse events and mortality between the groups. The neutral associations proved to be underpowered with trial sequential analysis. Conclusion: However observational studies show IFX as a better choice, according to the RCTs, choosing either CYS or IFX as rescue therapy for ASUC, the long-term outcomes are not different, although further large RCTs are warranted.

Report this publication


Seen <100 times